...from Aimmune Therapeutics Inc. (NASDAQ:AIMT) for peanut allergy; and a label extension for psoriatic arthritis for Tremfya guselkumab...
...GSK2696274) lumasiran (ALN-GO1) inclisiran (aln-pcssc, pcsk9si) Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Tremfya, guselkumab (CNTO 1959) Blincyto...

...“$500M Up Front”).The pharma’s immunology drugs include Remicade infliximab, Simponi golimumab, Stelara ustekinumab and Tremfya guselkumab...

...Tremfya The Janssen Pharmaceutical Cos. unit of Johnson & Johnson (NYSE:JNJ) said FDA approved Tremfya guselkumab...

...submissions by year end. Zai gained $2.02 to $40.25 on Friday. NMPA also approved Tremfya guselkumab...
...Johnson & Johnson (NYSE:JNJ) and a chickenpox vaccine from Sinovac Biotech Ltd. (NASDAQ:SVA) on Friday. Tremfya...

...inhibitors like Taltz ixekizumab could be the best bet over IL-23 inhibitors such as Tremfya guselkumab...
...69.1%, p=0.127). But by week 48, the numbers favored Tremfya, with 84.5% of patients receiving Tremfya...
...adalimumab (D2E7) Skyrizi, risankizumab (ABBV-066, BI 655066) Taltz (Brand), LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) Tremfya, guselkumab (CNTO 1959) AbbVie...

...to interrogate thousands of samples acquired in Janssen’s 200-patient VEGA trial of anti-IL-23A mAb Tremfya guselkumab...

...EULAR) meeting in Madrid. Tremfya meets in Phase III psoriatic arthritis trials Janssen said Tremfya guselkumab...

...of multiple competitor entries and new competitor data." In December, Janssen Biotech Inc. said Tremfya guselkumab...
...efficacy in treating moderate-to-severe plaque psoriasis compared with Cosentyx in a head-to-head Phase III trial. Tremfya...
...frequent dosing than Cosentyx and no signs of de novo inflammatory bowel disease (IBD) (see "Tremfya...

...of multiple competitor entries and new competitor data." In December, Janssen Biotech Inc. said Tremfya guselkumab...
...efficacy in treating moderate-to-severe plaque psoriasis compared with Cosentyx in a head-to-head Phase III trial. Tremfya...
...frequent dosing than Cosentyx and no signs of de novo inflammatory bowel disease (IBD) (see "Tremfya...